Gastric Cancer and the Immunotherapy Revolution: How Checkpoint Inhibitors Are Changing Survival Outcomes

By Editorial Team

Key Takeaways

  • Immunotherapy is now a standard treatment for many advanced gastric cancers.

  • MSI-H is the strongest predictor of response.

  • PD-L1 CPS testing is essential for treatment selection.

  • HER2-positive patients may benefit from combined targeted therapy and immunotherapy.

  • Some patients experience long-term durable remissions lasting years.

  • Future advances are likely to come from biomarker-driven precision medicine and combination approaches integrating immunotherapy, targeted therapy, and metabolic oncology.

Gastric Cancer and Immunotherapy

Abstract

Gastric cancer remains one of the leading causes of cancer-related deaths worldwide. Historically, treatment options for advanced gastric cancer were limited to surgery, chemotherapy, and palliative care, with median survival often measured in months. Over the past decade, however, immunotherapy has transformed the treatment landscape. Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have demonstrated meaningful survival benefits in selected patients, particularly those with high PD-L1 expression, microsatellite instability-high (MSI-H) tumors, or high tumor mutational burden (TMB). This review examines the evolution of immunotherapy in gastric cancer, key biomarkers predicting response, landmark clinical trials, emerging combination strategies, and future directions.

Introduction

Gastric cancer is the fifth most common cancer and the fourth leading cause of cancer mortality globally. Despite improvements in surgery, chemotherapy, and targeted therapies, the prognosis for advanced or metastatic gastric cancer remains poor.

The emergence of immunotherapy represents one of the most significant advances in gastric cancer treatment since the introduction of combination chemotherapy. Unlike conventional therapies that directly attack tumor cells, immunotherapy activates the patient's immune system to recognize and eliminate cancer cells.

For a subset of patients, the results have been remarkable, with some experiencing durable responses lasting years.

Understanding the Immune System's Role in Gastric Cancer

Cancer cells evade immune detection through several mechanisms:

  • Expression of PD-L1 proteins that suppress T-cell activity

  • Recruitment of immunosuppressive cells within the tumor microenvironment

  • Alteration of antigen presentation pathways

  • Creation of an inflammatory environment that favors tumor growth

Immune checkpoint inhibitors block these escape mechanisms, allowing T cells to attack cancer cells more effectively.

The most successful checkpoint pathways targeted in gastric cancer include:

  • PD-1 (Programmed Death-1)

  • PD-L1 (Programmed Death Ligand-1)

  • CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4)

Key Biomarkers Driving the Immunotherapy Revolution

PD-L1 Expression

PD-L1 expression is currently the most widely used biomarker for selecting gastric cancer patients for immunotherapy.

The Combined Positive Score (CPS) measures PD-L1 expression on both tumor and immune cells.

Generally:

  • CPS ≥1 may indicate some benefit

  • CPS ≥5 demonstrates greater benefit

  • CPS ≥10 often predicts stronger responses

Patients with higher PD-L1 expression consistently derive greater benefit from checkpoint inhibitors.

Microsatellite Instability-High (MSI-H)

MSI-H gastric cancers represent approximately 5–10% of cases.

These tumors:

  • Accumulate large numbers of mutations

  • Produce many neoantigens

  • Are highly visible to the immune system

Response rates to immunotherapy in MSI-H gastric cancer can exceed 50%, among the highest observed in solid tumors.

MSI-H status is now considered one of the strongest predictors of immunotherapy response.

Tumor Mutational Burden (TMB)

Tumors with high mutational burden generate more abnormal proteins that can be recognized by immune cells.

High TMB has been associated with:

  • Improved response rates

  • Longer progression-free survival

  • Greater overall survival

Although less commonly used than PD-L1 or MSI testing, TMB may help identify additional responders.

Epstein-Barr Virus (EBV)-Positive Gastric Cancer

Approximately 8–10% of gastric cancers are associated with Epstein-Barr virus.

These tumors frequently exhibit:

  • High PD-L1 expression

  • Significant immune infiltration

  • Strong immunogenicity

Several studies suggest EBV-positive gastric cancers may be among the most responsive subtypes to checkpoint inhibition.

Landmark Clinical Trials

KEYNOTE-059

The phase II KEYNOTE-059 trial evaluated the PD-1 inhibitor Pembrolizumab in previously treated advanced gastric cancer.

Key findings:

  • Durable responses observed in heavily pretreated patients

  • Better outcomes among PD-L1-positive tumors

  • Established proof-of-concept for immunotherapy in gastric cancer

This study helped pave the way for broader immunotherapy adoption.

CheckMate-649

The CheckMate-649 trial was a landmark study evaluating chemotherapy combined with the PD-1 inhibitor Nivolumab.

Results demonstrated:

  • Significant improvement in overall survival

  • Improved progression-free survival

  • Greatest benefit among patients with PD-L1 CPS ≥5

The trial established chemo-immunotherapy as a first-line standard of care for many advanced gastric cancer patients.

KEYNOTE-811

This trial focused on HER2-positive gastric cancer.

Researchers combined:

  • Pembrolizumab

  • Trastuzumab

  • Chemotherapy

The results showed substantially improved response rates compared with standard therapy alone.

This represented a major breakthrough for HER2-positive disease.

ATTRACTION-4

Conducted primarily in Asia, ATTRACTION-4 confirmed that nivolumab plus chemotherapy improved progression-free survival in advanced gastric cancer.

The findings reinforced the global role of checkpoint inhibition in first-line treatment.

Immunotherapy in Early-Stage Gastric Cancer

Recent research is extending immunotherapy into earlier disease stages.

Potential applications include:

  • Neoadjuvant treatment before surgery

  • Adjuvant treatment after surgery

  • Perioperative chemo-immunotherapy

Early studies suggest that integrating immunotherapy before surgery may improve pathological complete response rates and reduce recurrence risk.

Combination Strategies: The Next Frontier

Researchers are exploring combinations designed to overcome resistance.

Immunotherapy Plus Chemotherapy

Chemotherapy can:

  • Increase tumor antigen release

  • Enhance immune recognition

  • Improve T-cell infiltration

This strategy has become a new standard in many settings.

Immunotherapy Plus HER2 Targeting

HER2-targeted agents may enhance immune activation.

Promising combinations include:

  • Pembrolizumab + trastuzumab

  • Novel antibody-drug conjugates

  • Bispecific antibodies

Immunotherapy Plus Anti-Angiogenic Therapy

Anti-angiogenic drugs can normalize tumor blood vessels and improve immune-cell access.

Studies involving:

  • Ramucirumab

  • VEGF inhibitors

  • Multi-target tyrosine kinase inhibitors

have shown encouraging results.

Dual Checkpoint Blockade

Combining PD-1 and CTLA-4 inhibitors may:

  • Activate multiple immune pathways

  • Increase response rates

  • Potentially improve long-term survival

However, toxicity remains a challenge.

Why Some Patients Experience Extraordinary Responses

The immunotherapy revolution has produced a phenomenon rarely seen with traditional treatments: long-term survivors.

Several factors appear associated with exceptional responses:

  • MSI-H status

  • High PD-L1 expression

  • EBV positivity

  • High TMB

  • Robust T-cell infiltration

  • Favorable gut microbiome composition

Some patients remain disease-free for years after treatment initiation, suggesting that durable immune control may be achievable in select cases.

Challenges and Limitations

Despite impressive advances, most gastric cancer patients still do not achieve long-term benefit.

Current challenges include:

  • Primary resistance

  • Acquired resistance

  • Biomarker limitations

  • Immune-related adverse events

  • High treatment costs

Researchers continue to seek more accurate predictors of response.

Future Directions

Several emerging areas may further improve outcomes:

Personalized Immunotherapy

  • Genomic profiling

  • AI-driven biomarker discovery

  • Precision patient selection

Cellular Therapies

  • CAR-T therapies targeting Claudin 18.2

  • Tumor-infiltrating lymphocyte (TIL) therapy

  • Engineered T-cell receptor therapies

Cancer Vaccines

Personalized neoantigen vaccines may enhance immune recognition and work synergistically with checkpoint inhibitors.

Metabolic-Immunologic Combinations

Growing evidence suggests that tumor metabolism influences immune function. Future strategies may combine immunotherapy with metabolic interventions targeting glucose, glutamine, and mitochondrial pathways.

Practical Clinical Framework

For newly diagnosed advanced gastric cancer, clinicians increasingly evaluate:

  1. HER2 status

  2. PD-L1 CPS score

  3. MSI status

  4. TMB status

  5. Claudin 18.2 expression

  6. EBV status when available

These biomarkers help determine whether immunotherapy should be used alone, combined with chemotherapy, or integrated with targeted therapies.

Conclusion

The immunotherapy revolution has fundamentally altered the treatment paradigm for gastric cancer. What was once a disease with limited options now has multiple immune-based strategies capable of extending survival and, in some cases, producing durable long-term remissions. The greatest benefits are observed in biomarker-selected populations such as MSI-H, PD-L1-high, EBV-positive, and high-TMB tumors. As precision oncology advances and combination strategies mature, immunotherapy is poised to become an increasingly central component of gastric cancer management, offering renewed hope for patients facing one of the world's most challenging malignancies.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...
Read more

Archive

Show more